GlassScriptPhysician profile
Joseph M Malters
NPI 1689760233
$6,085.58
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $253 · 2021: $1,095 · 2022: $1,288 · 2023: $1,668 · 2024: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.03 |
| Education | $168.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,480.78 | 2019-2024 | |
| Janssen Biotech, INC. | $777.60 | 2019-2024 | Tremfya, Stelara, Remicade |
| Leo Pharma INC. | $534.16 | 2021-2024 | Adbry |
| Lilly USA, LLC | $449.40 | 2019-2024 | Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $380.73 | 2019-2023 | Blu-U, Odomzo, Ilumya |
| Ucb, INC. | $364.40 | 2019-2024 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $300.08 | 2019-2023 | |
| Amgen INC. | $287.69 | 2020-2024 | Otezla |
| Genzyme Corporation | $286.39 | 2019-2024 | |
| Celgene Corporation | $257.86 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $199.04 | 2019-2024 | Dupixent, Libtayo |
| Pfizer INC. | $197.41 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $140.45 | 2022-2024 | Sotyktu |
| Genentech USA, INC. | $108.91 | 2019-2022 | |
| Dermavant Sciences, INC. | $80.55 | 2023-2024 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $58.76 | 2021-2022 | |
| Incyte Corporation | $37.83 | 2022-2023 | Opzelura |
| Aclaris Therapeutics, INC. | $35.45 | 2019 | |
| Kyowa Kirin, INC. | $34.80 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.76 | 2023 | Spevigo |
| Fresenius Kabi USA, LLC | $22.38 | 2024 | Idacio |
| Almirall LLC | $14.86 | 2023 | Klisyri |
| Kerecis Limited | $11.29 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Malters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.